Gluscan

Gluscan is a radiopharmaceutical product that contains the active ingredient fluorodeoxyglucose labeled with fluorine‑18 (18F‑FDG) in a sterile solution for injection. It is supplied in an injectable form without a specified strength on the label and is authorized for prescription use within the European Union. Gluscan functions as a glucose analog that enables visualization of metabolic and quantitative activity during clinical PET imaging diagnostic procedures.

Gluscan is employed as a diagnostic imaging agent in positron emission tomography (PET) to assess metabolic activity in various clinical contexts.

- Oncologic PET imaging for tumor detection, staging, and therapeutic monitoring. - Cardiac PET imaging to evaluate myocardial viability and perfusion. - Neurologic PET imaging for assessment of epilepsy foci, dementia, and other brain disorders. - Research applications involving quantitative measurement of glucose metabolism in clinical trials. - Evaluation of inflammatory diseases where increased metabolic activity may indicate active inflammation.

Adverse reactions to Gluscan are generally infrequent, but they can be categorized by frequency and severity.

Common: - Transient flushing or warmth sensation at the injection site. - Mild nausea or vomiting shortly after administration. - Short‑lasting headache or dizziness. - Temporary metallic taste in the mouth. - Mild fatigue or feeling of weakness. - Minor injection site discomfort.

Serious: - Allergic reactions ranging from urticaria to anaphylaxis. - Severe hypoglycemia in patients with impaired glucose regulation. - Radiation‑related tissue injury in rare high‑dose exposures. - Cardiac arrhythmia triggered by metabolic stress. - Persistent neurological symptoms such as seizures in susceptible individuals.

Prior to administering Gluscan, clinicians should evaluate patient-specific factors and follow safety guidelines to minimize risks.

- Verify blood glucose level is within an acceptable range before injection. - Assess for known hypersensitivity to fluorodeoxyglucose or any component of the formulation. - Consider pregnancy and lactation status; use only if the diagnostic benefit outweighs potential fetal exposure. - Ensure appropriate radiation protection measures for staff and nearby individuals. - Adjust dosing for pediatric patients according to weight‑based protocols when applicable. - Review recent administration of other radiopharmaceuticals to avoid cumulative radiation dose.

Gluscan may interact with certain medications or conditions that affect glucose metabolism or radiation exposure.

Avoid: - Concurrent use of high‑dose insulin or oral hypoglycemic agents that could cause severe hypoglycemia. - Administration of other radiopharmaceuticals within a short interval, which may increase cumulative radiation dose.

Use with caution: - Patients receiving chemotherapy or targeted therapies that alter tumor metabolism. - Use in individuals with renal impairment affecting clearance of the tracer. - Concurrent contrast agents for CT may affect image interpretation; schedule appropriately. - Beta‑blockers or other drugs influencing myocardial glucose uptake in cardiac studies. - Medications that significantly alter systemic glucose levels, such as corticosteroids.